480 results on '"Campbell, Jonathan D"'
Search Results
2. Subsequent Indications in Oncology Drugs: Pathways, Timelines, and the Inflation Reduction Act
3. Cost-Effectiveness of HIV Screening in Emergency Departments: Results From the Pragmatic Randomized HIV Testing Using Enhanced Screening Techniques in Emergency Departments Trial
4. An Alternative Measure of Health for Value Assessment: The Equal Value Life-Year
5. Effect of State Immunization Information System Based Reminder/Recall for Influenza Vaccinations: A Randomized Trial of Autodialer, Text, and Mailed Messages
6. Effect of State Immunization Information System Centralized Reminder and Recall on HPV Vaccination Rates
7. Tradeoffs When Building and Running Cohort and Patient-Level Markov Simulation Models.
8. The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19
9. Criteria and Scoring Functions Used in Multi-criteria Decision Analysis and Value Frameworks for the Assessment of Rare Disease Therapies: A Systematic Literature Review
10. Economic and clinical burden of comorbidities among patients with acromegaly
11. Increased Odds of Ventricular Arrhythmias Associated with Selective Serotonin Reuptake Inhibitor Use among the Pediatric and Young Adult Population: A Case–Control Study
12. Effect of State Immunization Information System Based Reminder/Recall for Influenza Vaccinations: A Randomized Trial of Autodialer, Text, and Mailed Messages
13. Centralized Reminder/Recall to Increase Influenza Vaccination Rates: A Two-State Pragmatic Randomized Trial
14. Value of Information in Asia: Concepts, Current Use, and Future Directions
15. Performing Cost-Effectiveness Analyses to Support Policy Making: Key Lessons From the Assessment of Aducanumab
16. Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease
17. Medicare Part D Coverage of Drugs Selected for the Drug Price Negotiation Program
18. Asthma Cost-Effectiveness Analyses: Are We Using the Recommended Outcomes in Estimating Value?
19. Assessing the impact of caring for a child with Dravet syndrome: Results of a caregiver survey
20. The direct and indirect costs of Dravet Syndrome
21. Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States
22. Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation
23. Impact of Nonmedical Vaccine Exemption Policies on the Health and Economic Burden of Measles
24. Screening test recommendations for methicillin-resistant Staphylococcus aureus surveillance practices: A cost-minimization analysis
25. Relationship between early follow-up and readmission within 30 and 90 days after ischemic stroke
26. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis
27. Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations
28. Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value
29. Exploring asthma control cutoffs and economic outcomes using the Asthma Control Questionnaire
30. Risk Factors of Prescription Opioid Overdose Among Colorado Medicaid Beneficiaries
31. Measurement of utility in asthma: evidence indicating that generic instruments may miss clinically important changes
32. Validation of an algorithm for identifying MS cases in administrative health claims datasets
33. The promise of Immuno-oncology: implications for defining the value of cancer treatment
34. The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies
35. Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force
36. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study
37. Hospital-Acquired Pressure Ulcers at Academic Medical Centers in the United States, 2008–2012: Tracking Changes Since the CMS Nonpayment Policy
38. Comparative Effectiveness of Quality Improvement Interventions for Pressure Ulcer Prevention in Academic Medical Centers in the United States
39. Outcomes before and after treatment escalation to Global Initiative for Asthma steps 4 and 5 in severe asthma
40. Frequency of Continuous Glucose Monitoring use and Change in Hemoglobin A1C for Adults With Type 1 Diabetes in a Clinical Practice Setting
41. Dynamic Medication Adherence Modeling in Primary Prevention of Cardiovascular Disease: A Markov Microsimulation Methods Application
42. Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates
43. Cost-Effectiveness of Patent Foramen Ovale Closure Versus Medical Therapy for Secondary Stroke Prevention
44. Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
45. Societal Implications of Health Insurance Coverage for Medically Necessary Services in the U.S. Transgender Population: A Cost-Effectiveness Analysis
46. Comparative-Effectiveness Research to Aid Population Decision Making by Relating Clinical Outcomes and Quality-Adjusted Life Years
47. Pharmacoeconomics and outcomes research degree-granting PhD programs in the United States
48. Value of Public Health Funding in Preventing Hospital Bloodstream Infections in the United States
49. Economic Differences in Direct and Indirect Costs Between People With Epilepsy and Without Epilepsy
50. Asthma outcomes: Healthcare utilization and costs
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.